Author Index to Volume 27

ADLARD, P., BUZI, F., JONES, J., STANHOPE, R. and PREECE, M.A. Physiological growth hormone secreted during slow-wave sleep in short prepubertal children, 355

AKGUN, S. see Imperato-McGinley, J.

AMINO, N., WATANABE, Y., TAMAKI, H., IWATANI, Y. and MIYAI, K. In-vitro conversion of blocking type anti-TSH receptor by anti-human IgG anti-bodies, 615

ANDERSON, JR, G.H. see Streeten, D.H.P.

ARAN, O. see Galatzer, A.

ASTRUP, J. see Lindholm, J.

ATKINSON, A.B. see McCance, D.R.

BALFE, J.W. see Dimartino-Nardi, J.

BALESTRIERI, A. see Balzano, A.

BALZANO, A., MIGLIARI, R., SICA, V., SCARPA, R.M., PINTUS, C., LOVISELLI, A., USAI, E. and BALESTRIERI, A. The effect of androgen blockade on pulsatile gonadotrophin release and LH response to naloxone, 491

BARON, W. see Kraiem, Z.

BARTALENA, L. see Marcocci, C.

BASCHIERI, L. see Marcocci, C.

BEAUREGARD, H. see Serri, O.

BECH, K. see Bliddal, H.

BEGGS, D. see Leung, N.W.Y.

BEIT-HALACHMI, N. see Galatzer, A.

BELCHETZ, P.E. see Casson, I.F. BENKER, G. see Schulte, H.

BENRAAD, TH. J. see Smals, A.E.M.

BENSON, L. see Ljunghall, S.

BENSON, L. see Ljunghan, S

BERGER, P. see Schwarz, S.

BERNABEI, A. see Inaudi, P.

BERTAGNA, A. see Ghigo, E.

Bertrand, J.-H., Ritz, P., Reznik, Y., Grollier, G., Potier, J.-C., Evrad, C. and Mahoudeau, J.A. Sipple's syndrome associated with a large prolactinoma, 607

Besser, G.M. see Ross, R.J.M., also Thomas, D.J.B.

BEVAN, J.S., GOUGH, M.H., GILLMER, M.D.G. and BURKER, C.W. Cushing's syndrome in pregnancy: the timing of definitive treatment, 225

BHAGAT, C. see Stuckey, B.G.A.

Віто, S. see Mori, T.

BJERRE, P. see Lindholm, J.

BLACK, E.G., SHEPPARD, M.C. and HOFFENBERG, R. Serial serum thyroglobulin measurements in the

management of differentiated thyroid carcinoma,

BLACK, E.G. see Davis, J.R.E.

BLIDDAL, H., HEGEDÜS, L., HANSEN, J.M., BECH, K., VAN DER GAAG, R. and DREXHAGE, H.A. The relationships between serum T3 index, thyroid volume and thyroid stimulating, TSH receptor binding and thyroid growth stimulating antibodies in untreated Graves' disease, 75

BOEY, J. see Kung, A.W.C.

Boles, J.-M., Morin, J.-F. and Garre, M.A. Ultrasensitive assay of thyroid stimulating hormone in patients with acute non-thyroidal illness, 395

BONNEY, R.C. and FRANKS, S. Phospholipase C activity in human endometrium: its significance in endometrial pathology, 307

BORRAS, C.G. see Casanueva, F.F.

BORRELLI, P. see Loche, S.

BOSCARO, M., SONINO, N., RAMPAZZO, A. and MANTERO, F. Response of pituitary-adrenal hormone in patients with Cushing's disease before and after ketoconazole treatment, 461

Вгоок, C.G.D. see Hindmarsh, P., also Smith, P.J.

BURGER, H.G. see McLachlan, R.I.

BURGUERA, B. see Casanueva, F.F.

BURKE, C.W. see Bevan, J.S., also Ng, L.L.

Buzi, F. see Adlard, P.

CALLÀ, C. see De Rosa, G.

CAMANNI, F. see Ghigo, E.

CAVALLACCI, G. see Marocci, C.

CAPPA, M. see Loche, S.

CARTEL F. see Marcocci, C.

CASANUEVA, F.F., BORRAS, C.G., BURGUERA, B., LIMA, L., MURUAIS, C., TRESGUERRES, J.A.F. and DEVESA, J. Growth hormone and prolactin secretion after growth hormone-releasing hormone administration, in anorexia nervosa patients, normal controls and tamoxifen-pretreated volunteers, 517

CASSON, I.F., DAVIS, J.C., JEFFERYS, R.V., SILAS, J.H., WILLIAMS, J. and BELCHETZ, P.E. Successful management of Cushing's disease during pregnancy by transsphenoidal adenectomy, 423

CAVALLACCI, G. see Marcocci, C.

CECCHINI, L. see De Rosa, G.

CELLA, S.G. see Loche, S.

CHAN, T. see Wang, C.

- Chapman, A.J., Wilson, M.D., Obhrai, M., Sawers, R.S., Lynch, S.S., Royston, J.P. and Clayton, R.N. Effect of bromocriptine on LH pulsatility in the polycystic ovary syndrome, 571
- CHARLESWORTH, M. see Thomas, D.J.B.
- CHIODERA, P. see Coiro, V.
- CHLOND, C. see Pirke, K.M.
- Christensen, S.E., Week, J., Ørskov, H., Møller, N., Flyybjerg, A., Harris, A.G., Lund, E. and Jorgensen, J. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201–995 versus subcutaneous injection schedule in acromegalic patients, 297
- CLAYTON, R.N. see Chapman, A.J.
- COIRO, V. and CHIODERA, P. Effect of obesity and weight loss on the arginine vasopressin response to insulin-induced hypoglycaemia, 253
- COMTOIS, R. see Serri, O.
- CORDA, R. see Loche, S.
- CORSELLO, S.M. see De Rosa, G.
- CRAIG, R.K. see Williams, E.D.
- CRINO, A. see Loche, S.
- D'ANTONA, N. see Inaudi, P.
- DAVIES, P.S.W. see Ross, R.J.M.
- DAVIES, T.F. see Feldman, A.
- DAVIS, J.C. see Casson, I.F.
- DAVIS, J.R.E., BLACK, E.G. and SHEPPARD, M.C. Evaluation of a sensitive chemiluminescent assay for TSH in the follow-up of treated thyrotoxicosis. 563
- DE JUAN, M. see Puig, M.L.
- DE KRETSER, M. see McLachlan, R.I.
- DE LA TORRE, W. see Garcia-Ameijeiras, A.
- DE LEIVA, A. see Garcia-Ameijeiras, A.
- DE LEO, V. see Inaudi, P.
- DE ROSA, G., DELLA CASA, S., CORSELLO, S.M., CECCHINI, L. and CALLÀ, C. Autoimmune polyglandular syndrome, primary empty sella and acute lymphocytic leukaemia, 535
- DEGROOT, L.J. see Hughes, I.A.
- DEL Pozo, C. see Puig, M.L.
- DEL Pozo, E. see Lamberts, S.W.J.
- DELLA CASA, S. see De Rosa, G.
- DESAI, R.K. see Jialal, I.
- DEVESA, J. see Casanueva, F.F.
- DIAMOND, E.J. see Feldman, A.
- DIEGUEZ, C. see Valcavi, R.
- DIMARTINO-NARDI, J., STONER, E., MARTIN, K., BALFE, J.W., JOSE, P.A. and New, M.I. New findings in apparent mineralocorticosteroid excess, 49
- DINNEN, J.S. see Lazarus, J.H.
- DREXHAGE, H.A. see Bliddal, H.
- DRIFE, J.O., O'MALLEY, B.P. and ROSENTHAL, F.D. Long-term suppression of a testosterone-produc-

- ing ovarian tumour by oestrogen/progesterone therapy, 121
- ECONOMOU, E. see Livadas, D.P.
- Edwards, C.R.W. see Stewart, P.M.
- ERTEL, N.H. see Imperato-McGinley, J.
- EVANS, D.J. see Ng, L.L.
- EVANS, P.J. see Sturgess, M.L.
- EVRAD, C. see Bertrand, J.-H.
- FAEDDA, A. see Loche, S.
- FAURE, N. and LEMAY, A. Ovarian suppression in polycystic ovarian disease during 6 month administration of a luteinizing hormone-releasing hormone (LH-RH) agonist, 703
- FELBER, J.P. see Livada, D.P.
- FELDMAN, A., SINGH, A., DIAMOND, E.J., SCHWARTZ, A.E., FRIEDMAN, E.W. and DAVIES, T.F. Variability in production and immunoreactivity of in-vitro secreted human thyroglobulin, 691
- FICHTER, M.M. see Pirke, K.M.
- FINDLAY, J.K. see McLachlan, R.I.
- FLYVBJERG, A. see Christensen, S.E.
- FONESCA, M.E. and ZARATE, A. The significance of elevated levels of gastrin in patients with pituitary adenoma, 403
- FOTIADOU-PAPPA, H. see Livadas, D.P.
- FRANCHI, F. see Inaudi, P.
- FRANKLYN, J.A., GAMMAGE, M.D. and SHEPPARD, M.C. Amiodarone and thyroid hormone effects on anterior pituitary hormone gene expression, 373
- FRANKS, S. see Bonney, R.C.
- FRASER, H.M. see Ljunghall, S.
- FRIEDMAN, E.W. see Feldman, A.
- FRISCH, H. see Schwarz, S.
- Fu, K.H. see Kung, A.W.C.
- FUKAZAWA, H. see Yamamoto, M.
- FUKUDA, S. Correlation between function of the pituitary-thyroid axis and metabolism of catecholamines by the fetus at delivery, 331
- VAN DER GAAG, R. see Bliddal, H.
- GAER, N.W.Y. see Leung, N.W.Y.
- GALATZER, ARAN, O., BEIT-HALCHMI, N., NOFAR, E., RUBITCHEK, J., PERTZELAN, A. and LARON, Z. The impact of long-term therapy by a multidisciplinary team on education, occupation and marital status of growth hormone deficient patients after termination of therapy, 191
- GAMMAGE, M.D. see Franklyn, J.A.
- GARCIA-AMEJIEIRAS, A., DE LA TORRE, W., RODRI-GUEZ-ESPINOSA, J., PEREZ-PEREZ, A. and DE LEIVA, A. Does testosterone influence the poststimulatory levels of calcitonin in normal men? 545

GARRE, M.A. see Boles, J.-M.

GERSTEIN, H.C. see Iitaka, M.

GHIGO, E., MAZZA, E., IMPERIALE, E., MOLINATTI, P., BERTAGNA, A., CAMANNI, F. and MASSARA, F. Growth hormone responses to pyridostigmine in normal adults and in normal and short children, 669

GILLMER, M.D.G. see Bevan, J.S.

Gioffré, W. see Inaudi, P.

GIWERCMAN, A. see Lindholm, J.

GIWERCMAN, A. see Lindholm, J.

GLASER, B. see Kraiem, Z.

GOUGH, M.H. see Bevan, J.S.

GRIEVE, J. see Stewart, P.M.

GROLLIER, G. see Bertrand, J.-H.

GROSSMAN, A. see Ross, R.J.M.

GUTTERIDGE, D.H. see Stuckey, B.G.A.

HADDEN, D.R. see McCance, D.R. HALES, I.B. see Robinson, B.G.

HALL, R. see Hughes, I.A.

HAMILTON, D. see Schlechte, J.A.

HANSEN, J.M. see Bliddal, H.

HARDY, J. see Serri, O.

HARRIS, A.G. see Christensen, S.E.

HASHIDA, S. see Mori, T.

HEALY, D.L. see McLachlan, R.I.

HEGEDÜS, L. see Bliddal, H.

HENNIKER, A.J. see Robinson, B.G.

HERMOS, R.J. see Mitchell, M.L.

HERMUS, A.R.M.M. see Smals, A.E.M.

HINDMARSH, P., SMITH, P.J., BROOK, C.G.D. and MATTHEWS, D.R. The relationship between height velocity and growth hormone secretion in short prepubertal children, 581

Ho, K. see Robinson, B.G.

HOCKADAY, T.D.R. see Ng. L.L.

HOFFENBERG, R. see Black, E.G.

HOFLAND, L. see Lamberts, S.W.J.

HOLLOWAY, B. see Leung, N.W.Y.

HORROCKS, P.M. and LONDON, D.R. Effects of long term dexamethasone treatment in adult patients with congenital adrenal hyperplasia, 635

HUGHES, I.A., ICHIKAWA, K., DEGROOT, L.J., JOHN, R., JONES, M.K., HALL, R. and SCANLON, M.F. Non-adenomatous inappropriate TSH hypersecretion and euthyroidism requires no treatment, 475

ICHIKAWA, K. see Hughes, 475

IITAKA, M., IWATANI, Y., GERSTEIN, H.C., ROW, V.V. and VOLPÉ, R. Immunomodulatory effect of the treatment of Graves' disease on antigenspecific monocyte procoagulant activity production, 321

IIVANAINEN, M. see Pekkarinen, T.

IKEKUBO, K. see Mori, T.

IMPERATO-McGINLEY, J., AKGUN, S., ERTEL, N.H., SAYLI, B. and SHACKLETON, C. The coexistence of male pseudohermaphrodites with 17-ketosteroid reductase deficiency and 5-alpha-reductase deficiency within a Turkish kindred. 135

IMPERIALE, E. see Ghigo, E.

IMURA, H. see Mori, T.

IMURA, H. see Nakamura, H.

INAUDI, P., BERNABEI, A., GIOFFRÉ, W., FRANCHI, F., MAZZULLO, G., DE LEO, V. and D'ANTONA, N. Plasma and cyst fluid levels of Δ5 and Δ4 steroid hormones in women with gross cystic breast disease, 643

INOUE, S. see Mori, T.

ISHIKAWA, E. see Mori, T.

ITAGAKI, Y. see Yamamoto, M.

IWATANI, Y. see Amino, N., also Iitaka, M.

JEFFERYS, R.V. see Casson, I.F.

JIALAL, I., DESAI, R.K. and RAJPUT, M.C. An assessment of pituitary function in patients with Sheehan's syndrome, 91

JILWAN, N. see Serri, O.

JOHN, R. see Hughes, I.A.

JONES, J. see Adlard, P.

JONES, M.K. see Hughes, I.A.

JØRGENSEN, J. see Christensen, S.E.

Jose, P.A. see Dimartino-Nardi, J.

KAISE, K. see Yamamoto, M.

KARK, A.E. see Leung, N.W.Y.

KENNEDY, L. see McCance, D.R.

KENT, G.N. see Stuckey, B.G.A.

KLOPPENBORG, P.W.C. see Smals, A.E.M. KRAIEM, Z., LAHAT, N., GLASER, B., BARON, W., SADEH, O. and SHEINFELD, M. Thyrotrophin receptor blocking antibodies: incidence, charac-

terization and in-vitro synthesis, 409
KUNG, A.W.C., MA, J.T.C., WANG, C., FU, K.H.,
LAM, K.S.L., YEUNG, R.T.T. and BOEY, J. Prevention of hypoglycaemia in a patient with pancreatic
microadenomatosis by a long-acting analogue
SMS 201-995, 469

LADDAGA, M. see Marcocci, C.

LAESSLE, R.G. see Pirke, K.M. LAHAT, N. see Kraiem, Z.

LAING, I. see Sturgess, M.L.

LAM, K.S.L. see Wang, C.

LAM, K.S.L. see Kung, A.W.C.

LAMBERTS, S.W.J., VERLEUN, T., HOFLAND, L. and DEL POZO, E. A comparison between the effects of SMS 201–995, bromocriptine and a combination of both drugs on hormone release by the cultured pituitary tumour cells of acromegalic patients, 11

LAMBERT, A. see Robertson, W.R.

LARON, Z. see Galatzer, A.

LAZARUS, J.H., RICHARDS, A.R., MACPHERSON, M.J., DINNEN, J.S., WILLIAMS, E.D., OWEN, G.M. and WADE, J.S.H. Struma ovarii: a case report, 715

LEMAY, A. see Faure, N.

LEUNG, N.W.Y., GAER, J., BEGGS, D., KARK, A.E., HOLLOWAY, B. and PETERS, T.J. Multiple symmetric lipomatosis (Launois-Bensaude Syndrome): effect of oral salbutamol, 601

LEVIN, G.E. see Wilcox, A.H.

LIMA, L. see Casanueva, F.F.

LINDHOLM, J., GIWERCMAN, A., ASTRUP, J., BJERRE, P. and SKAKKEBÆK, N.E. Investigation of the criteria for assessing the outcome of treatment in acromegaly, 553

LIU, M.Y. see Wang, C.

LIVADAS, D.P., ECONOMOU, E., SOFRONIADOU, K., FOTIADOU-PAPPA, H., VAN MELLE, G.D., TEMLER, E. and Felber, J.P. A study of beta-cell function after glucagon stimulation in thalassaemia major treated by high transfusion programme, 485

LJUNGHALL, S., BENSON, L., RASTAD, J., WIDE, L. and AKERSTROM, G. Dynamic tests of parathyroid function for diagnosis of primary hyperparathyroidism in malignancy, 163

LOCATELLI, V. see SALERNO, F.

LOCHE, S., CAPPA, M., BORELLI, P., FAEDDA, A., CRINO, A., CELLA, S.G., CORDA, R., MÜLLER, E.E. and PINTOR, C. Reduced growth hormone response to growth hormone-releasing hormone in children with simple obesity: evidence for somatomedin-C mediated inhibition, 145

LONDON, D.R. see Horrocks, P.M. LOVERIDGE, N. see Robertson, W.R. LOVISIELLI, A. see Balzano, A. LUND, E. see Christensen, S.E. LUTJEN, P.J. see McLachlan, R.I. LUTTRELL, B.M. see Robinson, B.G. LYNCH, S.S. see Chapman, A.J.

Ma, J.T.C. see Kung, A.W.C., also Wang, C. MacPherson, M.J. see Lazarus, J.H.

MAHOUDEAU, J.A. see Bertrand, J.-H.

MANTERO, F. see Boscaro, M.

MARCOCCI, C., BARTALENA, L., PANICUCCI, M., MARCONCINI, C., CARTEI, F., CAVALLACCI, G., LADDAGA, M., CAMPOBASSO, G., BASCHIERI, L. and PINCHERA, A. Orbitol cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study, 33

MARCONCINI, C. see Marcocci, C. MARTIN, K. see Dimartino-Nardi, J.

MASSARA, F. see Ghigo, E.

MATTHEWS, D.R. see Hindmarsh, P.

MAZZA, E. see Ghigo, E.

MAZZULLO, G. see Inaudi, P.

McCance, D.R., Hadden, D.R., Kennedy, L., Sheridan, B. and Atkinson, A.B. Clinical experience with ketoconazole as a therapy for patients with Cushing's syndrome, 593

McLachlan, R.I., Healy, D.L., Lutjen, P.J., Findlay, J.K., De Kretser, D.M. and Burger, H.G. The maternal ovary is not the source of circulating inhibin levels during normal pregnancy, 663

McMillen, I.C. see Nowak, R.

Messinis, I. and Templeton, A. Effect of high dose exogenous oestrogen on midcycle luteinizing hormone surge in human spontaneous cycles, 453

MIGLIARI, R. see Balzano, A.

MITCHELL, M.L., HERMOS, R.J. and MOSES, A.C. Somatomedin-C/insulin-like growth factor-1 in infants with congenital hypothyroidism during the first week of life, 625

MIYAI, K. see Amino, N.

MOLINATT!, P. see Ghigo, E.

Møller, N. see Christensen, S.E.

MONCAYO, R. see Schwarz, S. MÖNIG. H. see Schulte, H.

Mori, T., Imura, H., Bito, S., Ikekubo, K., Inoue, S., Hashida, S., Ishikawa, E. and Ogawa, H. Clinical usefulness of a high sensitive enzyme-immunoassay of TSH, 1

MORI, T. see Nakamura, H.

MORIN, J.-F. see Boles, J.-M.

Moses, A.C. see Mitchell, M.L.

MOULT, P.J.A. see Woolf, A.S.

МРОКО, С.N. see Sturgess, M.L.

MÜLLER, E.E. see Loche, S., also Salerno, F.

MURUAIS, C. see Casanueva, F.F.

NAIRN, I.M. see Stewart, P.M.

NAKAMURA, H., SOMEDA, H., MORI, T. and IMURA, H. Thyrotrophin releasing hormone induce calcitonin secretion in patients with medullary carcinoma of the thyroid, 69

New, M.I. see Dimartino-Nardi, J.

NG, L.L., EVANS, D.J. and BURKE, C.W. The human leucocyte sodium pump in adrenocortical insufficiency, 235

NG, L.L. and HOCKADAY, T.D.R. The effect of oral glucose on the leucocyte sodium pump in normal and obese subjects, 345

NHAGAFOONG, L., see Ross, R.J.M.

NOFAR, E. see Galatzer, A.

NOMURA, T. see Yamamoto, M.

NOWAK, R., McMillen, I.C., Redman, J. and Short, R.V. The correlation between serum and salivary melatonin concentrations and urinary 6hydroxymelatonin sulphate excretion rates: two non-invasive techniques for monitoring human cicardian rhythmicity, 445

OBHRAI, M. see Chapman, A.J. OGAWA, H. see Mori, T. OHNHAUS, E.E. see Schulte, H. O'MALLEY, B.P. see Drife, J.O. ØRSKOV, H. see Christensen, S.E. OWEN, G.M. see Lazarus, J.H.

PADFIELD, P.L. see Stewart, P.M. PAGEL, H. see Schulte, H. PANICUCCI, M. see Marcocci, C. PARTINEN, M. see Pekkarinen, T.

PEKKARINEN, T., PARTINEN, M., PELKONEN, R. and IIVANAINEN, M. Sleep apnoea and daytime sleepiness in acromegaly: relationship to endocrinological factors, 649

PELKONEN, R. see Pekkarinen, T. PEREZ-PEREZ, A. see Garcia-Ameijeiras, A. PERTZELAN, A. see Galatzer, A. PETERS, T.J. see Leung, N.W.Y. PHILLIPS III, J.A. see Schwarz, S.

PIETERS, G.F.F.M. see Smals, A.E.M. PINCHERA, A. see Marcocci, C. PINTOR, C. see Loche, S.

PINTUS, C. see Balzano, A.

PIRKE, K.M., FICHTER, M.M., CHLOND, C., SCHEW-IGER, U., LAESSLE, R.G., SCHWINGENSCHLOEGEL, M. and HOEHL, C. Disturbances of the menstrual cycle in bulimia nervosa, 245 PONDER, B.J. see Williams, E.D.

PORTIOLI, I. see Valcavi, R. POTIER, J.-C see Bertrand, J.-H. PREECE, M. see Valcavi, R. PREECE, M.A. see Adlard, P.

PRICE, R.I. see Stuckey, B.G.A.

PRINGLE, P.J. see Smith, P.J.

PUIG, M.L., WEBB, S.M., DEL POZO, C., DE JUAN, M., SERRANO, S. and VILARDELL, E. Endocrine aspect of pituitary stalk enlargement, 25

PULLAN, P.T. see Stuckey, B.G.A.

RAFFERTY, B. see Smith, P.J. RAJPUT, M.C. see Jialal, I. RAMPAZZO, A. see Boscaro, M. RASTAD, J. see Ljunghall, S. REDMAN, J. see Nowak, R. REED, G.F. see Streeten, D.H.P. REES, L.H. see Ross, R.J.M. REINWEIN, D. see Schulte, H. REZNIK, Y. see Bertrand, J.-H. RICHARDS, A.R. see Lazarus, J.H. RITZ, P. see Bertrand, J.-H.

ROBERTSON, W.R., LAMBERT, A. and LOVERIDGE, N. Review: The role of modern bioassays in clinical endocrinology, 259

ROBERT, F. see Serri, O.

ROBERTSON, W.R. see Tsatsoulis, A.

ROBINSON, B.G., HALES, I.B., HENNIKER, A.J., HO. K., LUTTRELL, B.M., SMEE, I.R. and STIEL, J.N. The effect of o.p'-DDD on adrenal steroid replacement therapy requirements, 437

RODRIGUEZ-ESPINOSA, J. see Garcia-Ameijeiras, A. ROSENTHAL, F.D. see Drife, J.O.

Ross, R.J.M., GROSSMAN, A., DAVIES, P.S.W., SAVAGE, M.O. and BESSER, G.M. Stilboesterol pretreatment of children with short stature does not affect the growth hormone response to growth hormone-releasing hormone, 155

Ross, R.J.M, Tsagarakis, S., Grossman, A., Nha-GAFOONG, L., TOUZEL, R.J., REES, L.H. and BESSER, G.M. Rapid communication: GH feedback occurs through modulation of hypothalamic somatostatin under cholinergic control: studies with pyridostigmine and GHRH, 727.

Row, V.V. see Iitaka, M. ROYSTON, J.P. see Chapman, A.J. RUBITCHEK, J. see Galatzer, A.

SADEH, O. see Kraiem, Z. SAITO, S. see Yamamoto, M. SAKURADA, T. see Yamamoto, M.

SALERNO, F., LOCATELLI, V. and MULLER, E.E. Growth hormone hyperresponsiveness to growth hormone-releasing hormone in patients with severe liver cirrhosis, 183

SAVAGE, M.O. see Ross, R.J.M. SAWERS, R.S. see Chapman, A.J. SAYLI, B. see Imperato-McGinley, J. SCANLON, M.F. see Valcavi, R.

SCANLON, M.F. see Hughes, I.A. SCARPA, R.M. see Balzano, A.

SCHLECHTE, J.A. and HAMILTON, D. The effect of glucocortoids on corticosteroid binding globulin,

SCHULSTER, D. see Smith, P.J.

SCHULTE, H., MÖNIG, H., BENKER, G., PAGEL, H., REINWEIN, D. and OHNHAUS, E.E. Pharmacokinetics of aldosterone in patients with Addison's disease: effect of rifampicin treatment on glucocorticoid and mineralocorticoid metabolism, 655

SCHWARZ, S., BERGER, P., FRISCH, H., MONCAYO, R., PHILLIPS III, J.A. and WICK, G. Growth hormone blocking antibodies in a patient with the GH-N gene, 213

SCHWARTZ, A.E. see Feldman, A. SCHWEIGER, U. see Pirke, K.M. SCHWINGENSCHLOEGEL, M. see Pirke, K.M.

SERRANO, S. see Puig, M.L.


- Serra, O. Growth hormone releasing factor stimulates and somatostatin inhibits prolactin release from human mixed somatotroph-lactotroph adenomas in perifusion, 675
- SERRI, O., ROBERT, F., COMTOIS, R., JILWAN, N., BEAUREGARD, H., HARDY, J. and SOMMA, M. Distinctive features of prolactin secretion in acromegalic patients with hyperprolactinaemia, 429
- SHACKLETON, C. see Imperato-McGinley, J.
- SHALET, S.M. see Tsatsoulis, A.
- SHEINFELD, M. see Kraiem, Z.
- SHEPPARD, M.C. see Davis, J.R.E., also Franklyn, J.A.
- SHERIDAN, B. see McCance, D.R.
- SHORT, R.V. see Nowak, R.
- SICA, V. see Balzano, A.
- SILAS, J.H. see Casson, I.F.
- SINGH, A. see Feldman, A.
- SKAKKEBÆK, N.E. see Lindholm, J.
- SMALS, A.E.M., PIETERS, G.F.F.M., SMALS, A.G.H., HERMUS, A.R.M.M., BENRAAD, TH. J. and KLOPPENBORG, P.W.C. The higher the growth hormone response to growth hormone releasing hormone the lower the response to bromocriptine and thyrotrophin releasing hormone in acromegaly,
- SMALS, A.G.H. see Smals, A.E.M.
- SMEE, I.R. see Robinson, B.G.
- SMITH, P.J. and BROOK, C.G.D. The place of intravenous GHRH 1-40 studies in the therapy of growth hormone-deficient children with GHRH, 97
- SMITH, P.J., PRINGLE, P.J., BROOK, C.G.D., SCHULS-TER, D. and RAFFERTY, B. Plasma immunoreactive GHRH and serum GH concentration following pulsatile GHRH 1-40 administrations in GH deficient children, 501
- SMITH, P.J. see Hindmarsh, P.
- SOFRONIADOU, K. see Livadas, D.P.
- SOMEDA, H. see Nakamura, H.
- SOMMA, M. see Serri, O.
- SONINO, N. see Boscaro, M.
- ST JOHN, J. see Tsatsoulis, A.
- STANHOPE, R. see Adlard, P.
- STEWART, P.M., GRIEVE, J., NAIRN, I.M., PADFIELD, P.L. and EDWARDS, C.R.W. Lithium inhibits the action of fludrocortisone on the kidney, 63
- STIEL, J.N. see Robinson, B.G.
- STONER, E. see Dimartino-Nardi, J.
- STREETEN, D.H.P., ANDERSON JR, G.H., REED, G.F. and Woo, P. Prevalence, natural history and surgical treatment of exophthalmos, 125
- STUCKEY, B.G.A., KENT, G.N., GUTTERIDGE, D.H., PULLAN, P.T., PRICE, R.I. and BHAGAT, C. Fasting calcium excretion and parathyroid hormone together distinguish familial hypocalciuric hyper-

- calcaemia from primary hyperparathyroidism, 525
- STURGESS, M.L., WEEKS, I., EVANS, P.J., MPOKO, C.N., LAING, I. and WOODHEAD, J.S. An immuno-chemiluminometric assay for free serum thyroxine. 383
- TAMAKI, H. see Amino, N.
- TAYLOR, A. see Valcavi, R.
- TELMER, E. see Livadas, D.P.
- TEMPLETON, A. see Messinis, I.
- THOMAS, D.J.B., TOUZEL, R., CHARLESWORTH, M., WASS, J.A.H. and BESSER, G.M. Hyperprolactinaemia and microadenomas in primary hypothyroidism, 289
- Touzel, R. see Thomas, D.J.B.
- Touzel, R.J. see Ross, R.J.M.
- TRESGUERRES, J.A.F. see Casanueva, F.F.
- TSAGARAKIS, S. see Ross, R.J.M.
- TSATSOULIS, A., WHITEHEAD, E., ST JOHN, J., SHA-LET, S.M. and ROBERTSON, W.R. The pituitary-Leydig cell axis in men with severe damage to the germinal epithelium, 683

Usai, E. see Balzano, A.

- VALCAVI, R., DIEGUEZ, C., PREECE, M., TAYLOR, A., PORTIOLI, I. and SCANLON, M.F. Effect of thyroxine replacement therapy on plasma insulin-like growth factor I levels and growth hormone responses to growth hormone releasing factor in hypothyroid patients, 85
- VAN MELLE, G.D. see Livadas, D.P.
- VERLEUN, T. see Lamberts, S.W.J.
- VILARDELL, E. see Puig, M.L.
- VOLPÉ, R. see litaka, M.
- WADE, J.S.H. see Lazarus, J.H.
- WANG, C., LAM, K.S.L., MA, J.T.C., CHAN, T., LIU, M.Y. and YEUNG, R.T.T. Long-term treatment of hyperprolactinaemia with bromocriptine: effect
- of drug withdrawal, 363 Wang, C. see Kung, A.W.C.
- Wass, J.A.H. see Thomas, D.J.B.
- WATANABE, Y. see Amino, N.
- WEBB, S.M. see Puig, M.L.
- WEEKE, J. see Christensen, S.E.
- WEEKS, I. see Sturgess, M.L.
- WHITEHEAD, E. see Tsatsoulis, A.
- WICK, G. see Schwarz, S.
- WIDE, L. see Ljunghall, S.
- WILCOX, A.H. and LEVIN, G.E. Erythrocyte oubain binding in patients receiving thyroxine, 205
- WILLIAMS, E.D., PONDER, B.J. and CRAIG, R.K. Immunohistochemical study of calcitonin gene-

- related peptide in human medullary carcinoma and C cell hyperplasia, 107
- WILLIAMS, E.D. see Lazarus, J.H.
- WILLIAMS, J. see Casson, I.F.
- WILSON, M.D. see Chapman, A.J.
- Woo, P. see Streeten, D.H.P.
- WOODHEAD, J.S. see Sturgess, M.L.
- Woolf, A.S. and Moult, P.J.A. Rapid communication: Plasma levels of atrial natriuretic peptide in hyperthyroidism, 721
- YAMAMOTO, M., SAITO, S., SAKURADA, T., FUKA-
- ZAWA, H., YOSHIDA, K., KAISE, K., NOMURA, T., ITAGAKI, Y., YONEMITSU, K. and YOSHINAGA, K.Effect of prednisolone and salicylate on serum thyroglobulin level in patients with subacute thyroiditis, 339
- YEUNG, R.T.T. see Kung, A.W.C., also Wang, C. YONEMITSU, K. see Yamamoto, M.
- Yoshida, K. see Yamamoto, M.
- YOSHINAGA, K. see Yamamoto, M.
- ZARATE, A. see Fonesca, M.E.



Subject Index to Volume 27

ADH

in Sheehan's syndrome, 93

Acromegalic patients

and infusion of SMS 201-995, 297

effects of SMS 201-995 and bromocriptine on hormone release by pituitary cells, 11

Acromegaly

and sleep apnoea, 649

and prolactin secretion in hyperprolactinaemia,

criteria for assessing outcome of treatment, 553 inter-relationship between GH responses to GHRH, bromocriptine and TRH, 43

Acute non-thyroidal illness

ultrasensitive assay for TSH, 395

Acute lymphocytic leukaemia, 535

Adenectomy

and Cushing's disease, 423

Adrenal hyperplasia

effects of dexamethasone treatment, 635

Adrenal steroid

effect of o,p'-DDD on replacement therapy requirements, 437

Adrenocortical insufficiency

and human leucocyte sodium pump, 235

Aldosterone

in patients with Addison's disease, 655

Amiodarone

and pituitary hormone gene expression, 375

Androgen blockade

effect on pulsatile gonadotrophin release and LH response to naloxone, 491

Androgen production

and pseudohermaphroditism, 135

Anorexia nervosa

prolactin and GH secretion after GHRH administration, 517

Anti-human IgG antibodies

convert blocking anti-TSH receptor antibody to stimulating type, in vitro, 615

Antibodies

GH blocking, 213

thyrotrophin receptor blocking, 409

Antibody-specific monocyte procoagulant activity and Graves' disease, 321

Arginine vasopressin response to hypoglycaemia in obesity, 253

Atrial natriuretic peptide

in hyperthyroidism, 721

Autoimmune polyglandular syndrome, 535

Blocking type anti-TSH receptor antibody conversion to stimulating type, 615

Bromocriptine

and SMS 201-995 in acromegalic patients, 11

and LH pulsatility, 571

in hyperprolactinaemia, 363

response relative to that of GH to GHRH, in acromegaly, 43

in hyperprolactinaemia, 363

Bulimia nervosa

and disturbances of the menstrual cycle, 245

Buserelin

in premenstrual syndrome, 173

C cell hyperplasia

and calcitonin gene-related peptide, 107

Calcitonin secretion

in medullary carcinoma of the thyroid, 69

Calcitonin gene-related peptide (CGRP)

in C cell neoplasia, 107

Calcitonin levels in normal men effect of testosterone, 545

Case report

struma ovarii, 715

Catecholamines

and TSH, 331 B-Cell function

in thalassaemia major, 485

Chemiluminescent assay

for TSH in thyrotoxicosis follow-up, 563

Children

GH responses to pyridostigmine in, 669

Cholinergic control

and GH feedback, 727

Cirrhosis

and GHRH-induced GH rise, 183

Clinical endocrinology

and the role of modern bioassays, 259

Congenital adrenal hyperplasia

and long term dexamethasone treatment, 635

Corticosteroid binding globulin

effect of glucocorticoids, 197

Cushing's syndrome

in pregnancy, 225, 423

and ketoconazole treatment, 461

clinical experience with ketoconazole, 593

Cystic breast disease

levels of $\Delta 5$ and $\Delta 4$ steroid hormones, 643

o.p'-DDD

and adrenal steroid replacement

Dexamethasone

effect on long term treatment in adult patients with congenital adrenal hyperplasia, 635

Diagnosis

of primary hyperparathyroidism in malignancy, 163

Drug withdrawal

bromocriptine in hyperprolactinaemia, 363

Endocrinological factors

in sleep apnoea and daytime sleepiness in acromegaly, 649

Endometrial pathology

and phospholipase C activity, 307

Enzyme-immunoassay

highly sensitive of TSH, 1

Erythrocyte oubain binding

in patients receiving thyroxine, 205

Exophthalmos

prevalence, course and treatment, 125

Familial hypocalciuric hypercalcaemia

distinguished from primary hyperparathyroidism, 525

Fetus

and catecholamine metabolism at delivery, 331

GH

feedback through modulation of hypothalamic somatostatin under cholinergic control, 727

inverse relationship between percentages of peak GH increments to GHRH and to TRH in acromegalic patients, 46

inverse relation for GH responses to GHRH and Br. 43

GH-N gene deletion

and GH blocking antibodies, 213

GH blocking antibodies

in patient with GH-N gene deletion, 213

GH deficient children

and i.v. GHRH

and immunoreactive GHRH concentrations during GHRH therapy, 501

GH response

to RGF in hypothyroid patients undergoing thyroxine replacement therapy, 85

to i.v. GHRH in the therapy of growth hormonedeficient children, 97

to GHRH in obese children, 145

stilboesterol does not affect response to GHRH,

GH secretion

and sleep, 355

and anorexia nervosa, 517

GHRH

and GH feedback, 727

studies in children, 97

and pyridostigmine, 669

and stilboesterol, 157

induced GH rise in cirrhotic patients, 183

concentrations during GHRH therapy, 501

and height velocity in prepubertal children, 581

tests in obese children, 147 tests in anorexia nervosa, 517

GRF

effect on GH during thyroxine replacement therapy, 85

Gastrin

and pituitary adenomas, 403

Glucagon stimulation

and β -cell function in thalassaemia, 485

Glucocorticoids

effect on corticosteroid binding globulin, 197

Graves' disease

and treatment of exophthalmos, 125

and procoagulant activity, 321 Graves' ophthalmopathy

a comparative study, 33

Height velocity

and GHRH secretion in prepubertal children, 581

Hormone release

by cultured pituitary tumour cells of acromegalic patients, 11

Hormones

effect of flutamide, 491

Human circadian rhythmicity

monitoring of, 445

Human endometrium

and phospholipase C activity, 307

Human medullary carcinoma

and calcitonin gene-related peptide, 107

Human pregnancy

and circulating inhibin levels, 663

Human thyroglobulin

production and immunoreactivity, 691

6-Hydroxymelatonin sulphate excretion rates

and serum and salivary melatonin concentrations, 445

Hypoadrenalism

and leucocyte sodium transport, 235

Hypercalcaemia

and primary hyperparathyroidism, 163

diagnosis of, 527

Hyperparathyroidism

diagnosis in malignancy, 163

Hyperprolactinaemia

in primary hypothyroidism, 289

and bromocriptine treatment, 363

and prolactin secretion in acromegaly, 429

Hyperthyroidism

and plasma levels of atrial natriuretic peptide, 721

Hypoglycaemia

and arginine vassopressin response, 253

prevention in microadenomatosis, 469

Hypothalamic somatostatin

modulation in GH feedback, 727

Hypothyroidism

hyperprolactinaemia and microadenomas, 289

Hypothyroid newborns

Somatomedin-C/insulin-like growth factor-1 levels, 625

IGH-1 levels

and thyroxine replacement therapy, 85

in hypothyroidism, 85, 89

Immunochemiluminometric assay

for serum free thyroxine, 383

Immunohistochemical study

of calcitonin gene-related peptide, 107

Immunoreactivity

of in-vitro secreted human thyroglobulin, 691

Immunoreactive GHRH

concentrations during GHRH therapy, 501

Inappropriate TSH hypersecretion, 475

Inhibin

source of during human pregnancy, 663

Ketoconazole

and Cushing's disease, 461, 493

clinical experience with Cushing's syndrome, 593

17-Ketosteroid reductase deficiency, 135

LH pulsatility

and bromocriptine, 571

LH response to naloxane

and androgen blockade, 491

LHRH agonist

and ovarian suppression in polycystic ovarian

disease, 703

and premenstrual syndrome, 171

Launois-Bensaude syndrome

effect of oral salbutamol, 601

Leucocyte sodium pump

in adrenocortical insufficiency, 235

effect of oral glucose, 345

Male pseudohermaphroditism

enzyme defects affecting androgen production,

Maternal ovary

not the source of circulating inhibin during human pregnancy, 663

Medullary thyroid carcinoma

TRH induces calcitonin secretion, 69

Melatonin secretion

monitoring of, 447

Menstrual cycle

in bulimia nervosa, 245

Microadenomas

in primary hypothyroidism, 289

Mineralocorticoid metabolism

and Addison's disease, 655

Modern bioassays

role in clinical endocrinology, 259

Multiple symmetric lipomatosis

effect of oral salbutamol, 601

Obese children

and GHRH, 145

Obesity

and leucocyte sodium pump, 345

effect on arginine vasopressin response in hypo-

glycaemia, 253

Oestrogen/progesterone therapy

and suppression of testosterone from an ovarian tumour, 121

Oral glucose

and the leucocyte sodium pump, 345

Orbital cobalt irradiation

combined with retrilobular or systemic corticosteroids for Graves' ophthalmopathy, 33

Oubain

and thyroid hormone action, 205

Ovarian suppression

in polycystic ovarian disease, 703

Ovarian tumour

and suppression of testosterone, 121

Pancreatic microadenomatosis

prevention of hypoglycaemia, 469

Parathyroid function

and primary hyperthyroidism in malignancy, 163

Pharmacokinetics

of aldosterone in Addison's disease, 655

Phospholipase C activity

in human endometrium, 307

Pituitary surgery

and sleep apnoea in acromegalic patients, 649

Pituitary-Leydig cell axis

in men with severe damage to the germinal

epithelium, 683

Pituitary stalk enlargement endocrine aspects, 25

Pituitary function

in patients with Sheehan's syndrome, 91

Pituitary-thyroid axis

metabolism of catecholamines by the fetus, 331

Pituitary hormone gene expression

rituitary normone gene e

and Amiodarone, 373

Pituitary adenomas

and gastrin, 403

Pituitary-adrenal axis

response to corticotrophin releasing hormone in patients with Cushing's disease, 461

Plasma levels

of atrial netriuretic peptide in hyperthyroidism, 721

Polycystic ovarian disease

and administration of LH-RH agonist, 703

Polycystic ovary syndrome

effect of bromocriptine on LH pulsatility, 571

Prednisolone

effect on thyroglobulin levels in subacute thyroiditis, 339

Pregnancy

and Cushing's syndrome, 225

Premenstrual syndrome

and use of buserelin, 171

Pyridostigmine

and GH response to in normal adults and in normal and short children, 669

Primary hyperparathyroidism

distinguished from familial hypocalciuric hypercalcaemia, 525

Primary empty sella, 535

Procoagulant activity

in Graves' disease, 321

Production

of human thyroglobulin, 691

Progesterone/oestrogen therapy

and suppression of testosterone from an ovarian tumour, 121

Prolactin release

from human mixed somatotroph-lactotroph adenomas in perifusion, 675

Prolactin secretion

in acromegalic patients with hyperprolactinaemia, 429

following GHRH administration in anorexia nervosa, 517

Prolactinoma

and Sipple's syndrome, 607

Pulsatile gonadotrophin release

effect of androgen blockade, 491

Pyridostigmine

and GH feedback, 727

5-α-Reductase deficiency, 135

Retrolobular corticosteroids

combined with orbital cobalt irradiation for Graves' ophthalmopathy, 33

Rifampicin treatment

and Addison's disease, 655

SMS 201-995

and bromocriptine in acromegalic patients, 11 in acromegaly, 297

and microadenomatosis, 469

Salbutamol

effect on multiple symmetric lipomatosis (Launois-Bensaude syndrome), 601

Salicylate

effect on thyroglobulin levels in subacute thyroiditis, 339

Serum thyroglobulin

in thyroid cancer, 117

Sheehan's syndrome

and ADH function, 91

and posterior pituitary function, 91 Sipple's syndrome

and prolactinoma, 607

Sleep

and GH secretion, 355

Sleep apnoea

and daytime sleepiness in acromegaly, 649

Somatomedin-C

and GH response to GHRH in obese children,

Somatomedin-C/insulin-like growth factor-1 in hypothyroid newborns, 625

Somatostatin

inhibits prolactin release, 675

and GH feedback, 727

Somatostatin

analogue SMS 201-995, infusion vs s.c. injection in acromegalic patients, 297

analogue SMS 201-995 and microadenomatosis, 469

Somatotroph-lactotroph adenomas

in perifusion, 675

Δ5 and Δ4 Steroid hormones

in women with gross cystic breast disease, 643

Stilboesterol

and GHRH, 155

Struma ovarii, 715

Suppression of testosterone

in an ovarian tumour, 121

Systemic corticosteroids

combined with orbital cobalt irradiation for Graves' ophthalmopathy, 33

TRH

response relative to that of GH to GHRH, in acromegaly, 43

and calcitonin secretion in patients with medullary thyroid cancer, 69

TSH

and catecholamines, 331

and pituitary hormone gene expression, 373

assay in acute non-thyroidal illness, 395

assay in follow-up of treated thyrotoxicosis, 563 enzyme-immunoassay, clinical usefulness, 1

Tamoxifen

and anorexia nervosa, 517

Testosterone

effect on calcitonin levels in normal men, 545

Thyroglobulin

and management of thyroid cancer, 115 in subacute thyroiditis, 339 production and immunoreactivity, 691

Thyroid cancer

and serum thyroglobulin, 115

Thyrotoxicosis

TSH assay in follow-up after treatment, 563 Thyrotrophin receptor blocking antibodies, 409

Thyroxine

and erythrocyte oubain binding, 205 immunochemiluminometric assay for, 383

Transsphenoidal adenectomy

and Cushing's disease during pregnancy, 423

Treatmen

assessment of outcome in Acromegaly, 553

Ultrasensitive assay

for TSH in acute non-thyroidal illness, 395

Weight loss

effect on arginine vasopressin response in hypoglycaemia, 253